E2F5 and gastric cancer: Increased expression of E2F5 was correlated with favourable OS in all GC patients, HR = 0.64 (0.54–0.076), P=2.8 × 10−7 (Figure 5A), intestinal cancer patients, HR = 0.56 (0.41–0.76), P=0.00043 (Figure 5B) and diffuse GC patients, HR = 0.58 (0.41–0.81), P=0.0013 (Figure 5C).